EFFECT OF EXOGENOUS LUTEINIZING HORMONE (LH) SUPPLEMENTATION IN LONG-ACTING GONADOTROPIN-RELEASING HORMONE AGONIST (GNRHA) ASSISTED REPRODUCTIVE TECHNOLOGY (ART) CYCLES: A RETROSPECTIVE COHORT STUDY.

Chenyang Huang,Jingyu Liu,Yue Jiang,Yingchun Zhu,Na Kong,Haixiang Sun

DOI: https://doi.org/10.1016/j.fertnstert.2021.07.477

IF: 6.7

2021-01-01

Fertility and Sterility

Abstract:Timely and moderate LH secretion plays critical roles in follicle development and maturation. Exogenous LH supplementation was considered to improve the follicle and embryo quality, which lead to better pregnancy outcome in GnRHa cycles. However, the role of LH supplementation in GnRHa assisted reproductive technology (ART) cycles remains unclear so far. In this study, we tried to clarify the roles of exogenous LH supplementation on clinical outcomes in long-acting GnRHa cycles. This retrospective analysis was conducted on women who were undergoing long-acting GnRHa ART cycles in our reproductive medicine center from January 2017 to December 2020. ALL patients received GnRHa (long-acting triptorelin acetate, 3.75 mg) in early follicular phase, followed by recombinant FSH (rFSH) alone or combined with recombinant LH (rLH) / human menopausal gonadotropin (HMG). There were 2600 cycles included in our study. All data were divided into group A and B according to whether they were supplemented with exogenous LH. In order to investigate the roles of LH addition in cycles of different factors, all cycles were divided into subgroups according to their ages, basal LH levels and kinds of LH for supplementation. Exogenous LH addition was uncorrelated with clinical pregnancy rate (OR = 1.227, 95% CI: 0.901-1.672, p = 0.19) in Logistic regression analysis. In addition, patients under 35 years old who did not receive LH addition got more oocytes (16.60 ± 6.3 vs 14.0 ± 5.5, p < 0.01) and good-quality embryos (6.2 ± 4.0 vs 5.1 ± 3.2, p < 0.01), but the clinical pregnancy rate was not significantly improved. More oocytes (14.3 ± 5.3 vs 13.5 ± 5.8, p = 0.04) and high-quality embryos (5.1 ± 3.3 vs 4.9 ± 3.3, p = 0.04) were retrieved in rLH-supplemented cycles than those in HMG-supplemented cycles, but the clinical pregnancy rate was mildly lower. When only analyzing the LH-supplemented group, the rate of clinical pregnancy (68.2% vs 73.2%) and embryo implantation (55.9% vs 60.7%) were a little lower in cycles with basal LH less than 10 mIU/mL. Furthermore, a smooth fitting curve analysis showed that the clinical outcomes in the LH-supplemented group are improved observably of patients with higher basal LH level (> 20 mIU/mL). There was no obvious effect on embryo implantation and clinical pregnancy rates in non-selective patients receiving a long-acting GnRHa ART cycle with LH supplementation or not. For women less than 35 years old, LH supplementation is not necessary. When some patients need LH addition, HMG may have a slightly better effect on clinical outcomes than rLH. LH supplementation may be more beneficial for patients with a higher basal serum LH level ( > 20 mIU/mL).